Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Allogene Therapeutics, Inc. - Common Stock
(NQ:
ALLO
)
1.340
-0.030 (-2.19%)
Streaming Delayed Price
Updated: 3:03 PM EST, Dec 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Allogene Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Q3 2025 Earnings Beat and Pipeline Progress
↗
November 06, 2025
Allogene Therapeutics beat Q3 2025 earnings estimates with a narrower loss and reaffirmed its cash runway into 2027. The biotech also reported progress on its allogeneic CAR T pipeline.
Via
Chartmill
Topics
Earnings
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
October 20, 2025
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares...
Via
MarketMinute
Topics
Initial Public Offering
Regulatory Compliance
Workforce
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
↗
October 10, 2025
Via
Benzinga
Allogene Therapeutics's Earnings Outlook
↗
May 12, 2025
Via
Benzinga
A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics
↗
August 08, 2024
Via
Benzinga
Analyst Ratings For Allogene Therapeutics
↗
May 31, 2024
Via
Benzinga
Allogene Q2 Cash Tops $300 Million
↗
August 13, 2025
Via
The Motley Fool
Allogene Narrows Loss in Fiscal Q2
↗
August 13, 2025
Via
The Motley Fool
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q2 2025 Loss, Shares Rise Modestly
↗
August 13, 2025
Allogene Therapeutics reported a Q2 2025 net loss of $0.23 per share, beating estimates, with revenue at $0. Shares rose 1% post-earnings as investors focused on cost discipline and clinical progress.
Via
Chartmill
A Look at Allogene Therapeutics's Upcoming Earnings Report
↗
August 12, 2025
Via
Benzinga
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday
↗
August 04, 2025
Via
Benzinga
Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views
↗
May 15, 2024
Via
Benzinga
Earnings Scheduled For August 13, 2025
↗
August 13, 2025
Via
Benzinga
Allogene Resets Clinical Course After Patient Death In Lymphoma Study
↗
August 01, 2025
Allogene revised its LBCL trial after a fatal adverse event linked to ALLO-647, shifting to a standard FC regimen and updating its clinical approach.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
July 25, 2025
Via
Benzinga
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise
↗
February 23, 2025
Baird remains bullish on Allogene, stating that the updated cema-cel data continues to support the "differentiated durability" of its allogeneic CAR-T therapy.
Via
Stocktwits
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
↗
February 18, 2025
Via
Benzinga
Earnings Scheduled For May 13, 2025
↗
May 13, 2025
Via
Benzinga
Earnings Scheduled For March 13, 2025
↗
March 13, 2025
Via
Benzinga
Tuesday's session: gap up and gap down stocks
↗
February 18, 2025
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
Friday's session: top gainers and losers
↗
February 14, 2025
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Via
Chartmill
What's going on in today's session
↗
February 14, 2025
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Friday's session: gap up and gap down stocks
↗
February 14, 2025
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via
Chartmill
7 Biotech Stocks to Buy for Their Game-Changing Potential
↗
August 08, 2024
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.
Via
InvestorPlace
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
↗
July 19, 2024
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune...
Via
Benzinga
If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names
↗
May 28, 2024
Penny stocks to buy carry a great deal of risk. However, there are a few that look interesting after due diligence.
Via
InvestorPlace
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
May 21, 2024
Via
Benzinga
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
↗
May 21, 2024
Via
Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
↗
May 15, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
